Page 18 - Read Online

Page 12 of Ciardullo et al. Metab Target Organ Damage 2024;4:30 https://dx.doi.org/10.20517/mtod.2024.39

albuminuria in the general United States population. Dig Liver Dis 2021;53:866-72. DOI PubMed
43. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a
meta-analysis of observational cohort studies. Gut 2022;71:778-88. DOI PubMed
44. Shedlock K, Susi A, Gorman GH, Hisle-Gorman E, Erdie-Lalena CR, Nylund CM. Autism spectrum disorders and metabolic
complications of obesity. J Pediatr 2016;178:183-187.e1. DOI PubMed
45. Hydes TJ, Kennedy OJ, Glyn-Owen K, et al. Liver fibrosis assessed via noninvasive tests is associated with incident heart failure in a
general population cohort. Clin Gastroenterol Hepatol 2024;22:1657-67. DOI PubMed
46. Kasper P, Martin A, Lang S, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol 2021;110:921-37. DOI
PubMed PMC
47. Ciardullo S, Morabito G, Rea F, Savaré L, Perseghin G, Corrao G. Time trends in liver-related mortality in people with and without
diabetes: results from a population based study. J Clin Endocrinol Metab 2024;20:dgae182. DOI PubMed
48. Younossi ZM, Stepanova M, Ong J, et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver
transplantation in the United States. Clin Gastroenterol Hepatol 2021;19:580-589.e5. DOI PubMed
49. Karlsen TH, Sheron N, Zelber-Sagi S, et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans
against liver disease complications and premature mortality. Lancet 2022;399:61-116. DOI PubMed
50. Israelsen M, Juel HB, Detlefsen S, et al; GALAXY and MicrobLiver consortiak. Metabolic and genetic risk factors are the strongest
predictors of severity of alcohol-related liver fibrosis. Clin Gastroenterol Hepatol 2022;20:1784-1794.e9. DOI PubMed
51. Kim HS, Xiao X, Byun J, et al. Synergistic Associations of PNPLA3 I148M Variant, Alcohol intake, and obesity with risk of
cirrhosis, hepatocellular carcinoma, and mortality. JAMA Netw Open 2022;5:e2234221. DOI PubMed PMC
52. World Health Organization. Global status report on alcohol and health 2018. Available from: https://www.who.int/publications/i/
item/9789241565639[DOI:10.4324/9780203029732-13.
53. Griswold M G, Fullman N, Hawley C, et al. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic
analysis for the Global Burden of Disease Study 2016. Lancet 2018;392:1015-35. DOI PubMed PMC
54. 2020 Alcohol Collaborators. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic
analysis for the global burden of disease study 2020. Lancet 2022;400:185-235. DOI PubMed PMC
55. Sehrawat TS, Arab JP, Liu M, et al. Circulating extracellular vesicles carrying sphingolipid cargo for the diagnosis and dynamic risk
profiling of alcoholic hepatitis. Hepatology 2021;73:571-85. DOI PubMed PMC
56. Nasr P, Wester A, Ekstedt M, et al. Misclassified alcohol-related liver disease is common in presumed metabolic dysfunction-
associated steatotic liver disease and highly increases risk for future cirrhosis. Clin Gastroenterol Hepatol 2024;22:1048-1057.e2.
DOI PubMed
57. Conigrave KM, Saunders JB, Reznik RB. Predictive capacity of the AUDIT questionnaire for alcohol-related harm. Addiction
1995;90:1479-85. DOI PubMed
58. Staufer K, Huber-Schönauer U, Strebinger G, et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in
presumed non-alcoholic fatty liver disease. J Hepatol 2022;77:918-30. DOI
59. Kintz P. 2014 consensus for the use of alcohol markers in hair for assessment of both abstinence and chronic excessive alcohol
consumption. Forensic Sci Int 2015;249:A1-2. DOI PubMed
60. Room R. Stigma, social inequality and alcohol and drug use. Drug Alcohol Rev 2005;24:143-55. DOI PubMed
61. Schomerus G, Lucht M, Holzinger A, Matschinger H, Carta MG, Angermeyer MC. The stigma of alcohol dependence compared with
other mental disorders: a review of population studies. Alcohol Alcohol 2011;46:105-12. DOI PubMed
62. Younossi ZM, Alqahtani SA, Alswat K, et al; Global NASH Council. Global survey of stigma among physicians and patients with
nonalcoholic fatty liver disease. J Hepatol 2024;80:419-30. DOI PubMed
63. Lonardo A, Bril F, Caldwell SH, et al. Researchers call for more flexible editorial conduct rather than abruptly adopting only the new
MASLD nomenclature. J Hepatol 2024;80:e192-4. DOI PubMed
64. Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: a
systematic review with comparative analysis. World J Gastroenterol 2018;24:3361-73. DOI PubMed PMC
65. Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for
the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver
disease. J Hepatol 2016;64:1388-402. DOI PubMed PMC
66. Glen J, Floros L, Day C, Pryke R; Guideline Development Group. Non-alcoholic fatty liver disease (NAFLD): summary of NICE
guidance. BMJ 2016;354:i4428. DOI PubMed
67. Wong VW, Chan WK, Chitturi S, et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1:
Definition, risk factors and assessment. J Gastroenterol Hepatol 2018;33:70-85. DOI PubMed
68. Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future
directions. Dig Liver Dis 2017;49:471-83. DOI PubMed
69. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international
expert consensus statement. J Hepatol 2020;73:202-9. DOI PubMed
70. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new
fatty liver disease nomenclature. Ann Hepatol 2024;29:101133. DOI PubMed PMC
71. Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver